Business Context and Reporting Period
This Form 8-K, filed on April 11, 2017, by Tokai Pharmaceuticals, Inc. (noting the input metadata reference to Eledon Pharmaceuticals appears to be a discrepancy as the filing text explicitly identifies Tokai), serves as a supplement to a Definitive Proxy Statement regarding the proposed acquisition of Otic Pharma, Ltd. ("Otic"). The filing addresses stockholder litigation challenging the transaction and provides updated disclosures regarding the strategic review process, financial advisor opinions, and pro forma cash estimates.
Key Financial Metrics and Projections
The filing does not report historical revenue, profit, or cash flow for Tokai or Otic, as Otic currently has no revenue. However, it provides prospective expense forecasts for Otic prepared by management and reviewed by financial advisor Wedbush, assuming a transaction closing around February 28, 2017:
- Projected Otic Expenses (2017-2021):
- SG&A: $26.7 million total over 5 years.
- R&D: $68.7 million total over 5 years.
- Total Expenses: $95.5 million over 5 years.
- Tokai Cash Position: Tokai revised its estimate of net cash at the closing of the transaction from approximately $25.0 million to approximately $20.0 million.
- Market Data: The filing includes comparative market capitalization and enterprise value data for peer biotechnology companies, with mean market capitalization of $287.2 million and median of $302.0 million as of December 20, 2016.
Material Changes and Disclosures
The filing supplements the original proxy statement with the following material clarifications:
- Strategic Alternatives: Clarified that third parties expressing interest in Tokai were only interested in reverse mergers, not acquiring Tokai's galeterone or ARDA programs. Management ascribed minimal value to these programs and projected no future revenue from them.
- Standstill Provisions: Disclosed that confidentiality agreements with certain third parties (Company A, B, and C) included standstill provisions preventing them from making acquisition offers or seeking control of Tokai for specified periods.
- Financial Advisor Scope: Clarified that Wedbush did not perform discounted cash flow or multiples-based analyses for Otic due to its lack of revenue and uncertain forecasts. Wedbush also did not evaluate solvency or fair value under bankruptcy laws.
- Transaction Process: Confirmed that Tokai did not communicate with Company A regarding a revised merger draft nor with Company C regarding its "best and final offer," continuing diligence instead.
Guidance, Risks, and Contingencies
Stockholder Litigation: Two putative securities class actions (Bushansky v. Tokai and Wilson v. Tokai) were filed in the U.S. District Court for the District of Massachusetts. Plaintiffs allege false and misleading statements in the proxy statement regarding the Otic Transaction. The Company denies wrongdoing and intends to defend vigorously but is providing supplemental disclosures to avoid delaying the transaction.
Forward-Looking Risks: The filing highlights risks regarding the sufficiency of cash resources to fund operations, the ability to obtain regulatory approvals for Otic's product candidates (OP-01 and OP-02), and the uncertainty of clinical trial results. Actual results may differ materially from projections.
Transaction Status: A special meeting of stockholders is scheduled for May 9, 2017, to vote on the acquisition of Otic in exchange for Tokai common stock.
Investor Verification Checklist
- Verify the status of the two pending securities class actions and any potential impact on the May 9, 2017, stockholder vote.
- Confirm the revised net cash estimate of $20.0 million at closing and its sufficiency to fund Otic's projected $95.5 million in expenses over five years.
- Review the "Risk Factors" section of the Definitive Proxy Statement (referenced on page 30) for detailed risks regarding clinical trials and regulatory approvals.
- Assess the implications of the standstill provisions with third parties on future strategic alternatives for Tokai.
- Monitor the development plans for Otic's OP-01 (reformulation) and OP-02 as disclosed in the supplement.